• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?

tetano

Editor, Senior Moderator
PLoS One


. 2020 Aug 5;15(8):e0237127.
doi: 10.1371/journal.pone.0237127. eCollection 2020.
SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?


Daniel G Federman[SUP] 1 2 [/SUP], Shaili Gupta[SUP] 1 2 [/SUP], Gary Stack[SUP] 1 2 [/SUP], Sheldon M Campbell[SUP] 1 2 [/SUP], David R Peaper[SUP] 1 2 [/SUP], Louise M Dembry[SUP] 1 2 [/SUP], Ann Fisher[SUP] 1 2 [/SUP], Asim F Tarabar[SUP] 1 2 [/SUP], Michael Kozal[SUP] 1 2 [/SUP], Christopher B Ruser[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background: The global pandemic of Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV2) has resulted in unprecedented challenges for healthcare systems. One barrier to widespread testing has been a paucity of traditional respiratory viral swab collection kits relative to the demand. Whether other sample collection kits, such as widely available MRSA nasal swabs can be used to detect SARS-CoV-2 is unknown.
Methods: We compared simultaneous nasal MRSA swabs (COPAN ESwabs ? 480C flocked nasal swab in 1mL of liquid Amies medium) and virals wabs (BD H192(07) flexible mini-tip flocked nasopharyngeal swabs in 3mL Universal Transport Medium) for SARS-CoV-2 PCR testing using Simplexa COVID-19 Direct assay on patients over a 4-day period. When the results were discordant, the viral swab sample was run again on the Cepheid Xpert Xpress ? SARS-CoV-2 assay.
Results: Of the 81 included samples, there were 19 positives and 62 negatives in viral media and 18 positives and 63 negative in the MRSA swabs. Amongst all included samples, there was concordance between the COPAN ESwabs ? 480C and the viral swabs in 78 (96.3%).
Conclusion: We found a high rate of concordance in test results between COPAN ESwabs ? 480C in Amies solution and BD H192(07) nasopharyngeal swabs in in 3 mL of Universal Viral Transport medium viral media. Clinicians and laboratories should feel better informed and assured using COPAN ESwabs ? 480C to help in the diagnosis of COVID-19.
 
Back
Top Bottom